GNPX
Genprex, Inc. Common Stock
stockNASDAQ
genprex is mapping the future of cancer care. genprex's mission is to address the unmet medical needs of a growing population of cancer patients worldwide, through the development of a novel class of cancer drugs: immunogene therapy. our revolutionary clinical-stage products work synergistically with other approved and pipeline drugs to expand clinical indications for various cancers. about oncoprex® and lung cancer lung cancer is the second most common cancer in the u.s. but the leading cause of cancer death. there are approximately 225,000 new lung cancer cases in the u.s. per year and 1.8 million worldwide. the 5-year survival rate of stage iv non-small cell lung cancer (nsclc) is less than 1%, and treatment options beyond chemotherapy are lacking. approved nsclc targeted treatment options outside of chemo/radiation therapies only benefit a minority of patients. oncoprex® may now fill that gap by offering a targeted treatment option for a majority of nsclc patients. oncoprex® is cur
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 2.85 | 2026-09-29 | -8.07% | 4.900 |
| 1M | 3.54 | 2026-09-08 | -25.99% | 1.424 |
| 3M | 13.66 | 2026-07-06 | -80.82% | 0.423 |
| 6M | 31.90 | 2026-04-06 | -91.79% | 0.743 |
| 1Y | 224.73 | 2025-10-06 | -98.83% | 1.667 |
| 2Y | 384.89 | 2024-10-07 | -99.32% | — |
| 5Y | 113,520.00 | 2021-10-06 | -100.00% | 1.143 |
Genprex, Inc. Common Stock (NASDAQ:GNPX) stock price today is $2.62, and today's volume is 144,327. GNPX is down 3.676% today. The 30 day average volume is 177,424. GNPX market cap is $2.15M with 819,709 shares outstanding.